Fennec Pharmaceuticals Inc Forecasted to Earn FY2022 Earnings of ($0.91) Per Share (NASDAQ:FENC)

Fennec Pharmaceuticals Inc (NASDAQ:FENCGet Rating) – Equities research analysts at Cantor Fitzgerald cut their FY2022 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, November 22nd. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($0.91) per share for the year, down from their previous estimate of ($0.70). Cantor Fitzgerald has a “Overweight” rating and a $12.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.80) per share. Cantor Fitzgerald also issued estimates for Fennec Pharmaceuticals’ FY2023 earnings at ($0.78) EPS.

Fennec Pharmaceuticals (NASDAQ:FENCGet Rating) last posted its quarterly earnings data on Friday, November 11th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.14).

A number of other research analysts have also recently commented on FENC. Craig Hallum reissued a “buy” rating and issued a $14.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, August 8th. Maxim Group raised their price objective on Fennec Pharmaceuticals from $10.00 to $15.00 in a research note on Thursday, September 29th. Capital One Financial initiated coverage on Fennec Pharmaceuticals in a research note on Wednesday, September 7th. They set an “overweight” rating and a $11.00 price objective on the stock. HC Wainwright raised their price objective on Fennec Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, October 20th. Finally, Wedbush raised their price objective on Fennec Pharmaceuticals from $11.00 to $19.00 in a research note on Monday, September 26th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.83.

Fennec Pharmaceuticals Trading Down 0.2 %

Shares of FENC stock opened at $9.51 on Thursday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 10.30 and a current ratio of 10.30. Fennec Pharmaceuticals has a 52-week low of $3.82 and a 52-week high of $9.87. The company has a market capitalization of $249.54 million and a PE ratio of -11.60. The business’s fifty day moving average is $8.13 and its 200 day moving average is $6.91.

Institutional Trading of Fennec Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. UBS Group AG boosted its holdings in shares of Fennec Pharmaceuticals by 4,742.2% during the third quarter. UBS Group AG now owns 3,099 shares of the company’s stock worth $26,000 after purchasing an additional 3,035 shares during the period. Hartford Financial Management Inc. boosted its holdings in shares of Fennec Pharmaceuticals by 14.3% during the third quarter. Hartford Financial Management Inc. now owns 39,848 shares of the company’s stock worth $323,000 after purchasing an additional 5,000 shares during the period. Jane Street Group LLC purchased a new stake in Fennec Pharmaceuticals in the third quarter worth about $118,000. JPMorgan Chase & Co. lifted its holdings in Fennec Pharmaceuticals by 23,280.0% in the first quarter. JPMorgan Chase & Co. now owns 16,366 shares of the company’s stock worth $91,000 after buying an additional 16,296 shares during the period. Finally, DG Capital Management LLC lifted its holdings in Fennec Pharmaceuticals by 4.4% in the first quarter. DG Capital Management LLC now owns 1,210,638 shares of the company’s stock worth $6,780,000 after buying an additional 51,249 shares during the period. 43.29% of the stock is currently owned by hedge funds and other institutional investors.

About Fennec Pharmaceuticals

(Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Stories

Earnings History and Estimates for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.